-21%

est. 2Y upside i

Healthcare

Rank

#2780

Sector

Healthcare Technology

Est. Liquidity

~4Y

Data Quality

Data: Low

Given the lack of current valuation data and a stale PE round from 2022, the equity upside is highly uncertain.

Last updated: July 19, 2026

Bull (10%)+15%

If an IPO window opens and the company demonstrates category leadership, multiple could expand to 4x, yielding 30.4% pre-dilution upside; after 15% dilution, net upside ~15.4%.

Base (45%)-17%

Multiple converges to public comp average of 3x, with revenue growth at 10% CAGR; after 15% dilution, net downside ~17.2%.

Bear (45%)-34%

Multiple compresses to 2.5x due to competitive pressure from Epic/Cerner and slowing growth; after 15% dilution, net downside ~33.5%.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Funding Intensity

0%

Total funding amount unknown; assuming standard 1x non-participating preferred from GTCR's investment, preference overhang could be significant but not quantifiable.

Dilution Risk

moderate

Last round 4+ years ago; may require new capital, diluting existing common by estimated 15%.

Secondary Liquidity

none

No secondary transactions reported; employee equity likely illiquid until exit.

Questions to Ask at the Interview

Strategic questions based on DocuTAP's data — designed to show you've done your homework.

  • 1

    “How does Experity's AI strategy differentiate from Epic's ambulatory products?”

  • 2

    “What is the expected revenue growth and profitability trajectory over the next 2 years?”

  • 3

    “Given the 2022 PE round, what is the timeline for an exit and how does that affect equity value for employees?”

Community

Valuation Sentiment

Our model estimates -21% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.